0.7314

1.57% 0.0113

After Hours: .72 -0.0114 -1.56%

Scynexis Inc (SCYX)

Overview News Price History Option Chain Financials Why SCYX Down? Discussions Forecast Stock Split

Scynexis Inc stock is traded at $0.7314, with a volume of 70,952. It is up +1.57% in the last 24 hours and down -17.24% over the past month. SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Previous Close:

$0.7201

Open:

$0.72

24h Volume:

70,952

Relative Volume:

0.56

Market Cap:

$34.52M

Revenue:

$135.87M

Net Income/Loss:

$72.20M

P/E Ratio:

0.5151

EPS:

1.42

Net Cash Flow:

$45.09M

1W Performance:

-0.69%

1M Performance:

-17.24%

6M Performance:

-48.13%

1Y Performance:

-62.30%

1-Day Range:

$0.72

$0.75

1-Week Range:

$0.66

$0.77

52-Week Range:

$0.66

$2.29

Scynexis Inc Stock (SCYX) Company Profile

Name

Scynexis Inc

Sector

Healthcare (1160)

Industry

Drug Manufacturers - Specialty & Generic (83)

Phone

201-884-5485

Address

1 EVERTRUST PLAZA, JERSEY CITY, NJ

Employee

Twitter

@scynexis

Next Earnings Date

2024-11-11

Latest SEC Filings

SCYX's Discussions on Twitter

Compare SCYX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SCYX Scynexis Inc	0.7314	34.52M	135.87M	72.20M	45.09M	1.42
RGC Regencell Bioscience Holdings Ltd	22.99	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	159.18	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.25	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	15.34	47.39B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	17.01	20.17B	16.54B	-1.64B	749.00M	-1.45

Scynexis Inc Stock (SCYX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-22-21	Initiated	Guggenheim	Buy
Jan-06-21	Initiated	Cantor Fitzgerald	Overweight
Jul-11-18	Upgrade	Needham	Hold → Buy
Jun-27-18	Initiated	Maxim Group	Buy
Oct-24-17	Initiated	Guggenheim	Buy
Jul-10-17	Initiated	ROTH Capital	Buy
May-09-17	Downgrade	Needham	Buy → Hold
Mar-03-17	Reiterated	RBC Capital Mkts	Outperform
Oct-20-16	Initiated	H.C. Wainwright	Buy
Oct-07-16	Upgrade	WBB Securities	Buy → Strong Buy
Oct-03-16	Resumed	Brean Capital	Buy
Aug-17-16	Initiated	Guggenheim	Buy
Aug-09-16	Reiterated	Needham	Buy
Aug-09-16	Upgrade	WBB Securities	Speculative Buy → Buy
Mar-28-16	Initiated	Brean Capital	Buy
Dec-29-15	Initiated	WBB Securities	Speculative Buy
Nov-16-15	Reiterated	RBC Capital Mkts	Outperform
Jun-10-15	Initiated	Needham	Buy
May-29-14	Initiated	Canaccord Genuity	Buy
May-29-14	Initiated	RBC Capital Mkts	Outperform

View All

Scynexis Inc Stock (SCYX) Latest News

Jun 15, 2025

Millennium Management LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 15, 2025

Jun 11, 2025

Squarepoint Ops LLC Takes Position in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 11, 2025

Jun 10, 2025

Jane Street Group LLC Buys New Holdings in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 10, 2025

Jun 06, 2025

Bright Minds Biosciences (NASDAQ:DRUG) & SCYNEXIS (NASDAQ:SCYX) Head-To-Head Survey - Defense World

Jun 06, 2025

Jun 03, 2025

Northern Trust Corp Has $186,000 Stake in SCYNEXIS, Inc. (NASDAQ:SCYX) - Defense World

Jun 03, 2025

May 29, 2025

Scynexis resumes dosing in Phase III MARIO study after lengthy delay - MSN

May 29, 2025

SCYNEXIS resumes Phase 3 antifungal study after FDA lift By Investing.com - Investing.com South Africa

May 29, 2025